Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- EL +14.6% (also expanding its Profit Recovery Plan for fiscal years 2025 and 2026 to include a restructuring program; to cut 3-5% of positions) NSSC +7.9%, L +7.3%, CNA +5%, CAT +4.4%, TSN +3.8%
Other news:
- FDMT +64.3% (presents interim data from randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in Wet AMD)
- EVBG +18.3% (enters into definitive agreement to be acquired by Thoma Bravo for $1.5 billion or $28.60/share in cash)
- CTLT +11.4% (to be acquired by Novo Holdings for $63.50/share in cash)
- HAYN +6.6% (announces agreement to be acquired by North American Stainless)
- PLRX +5.7% (reports safety and exploratory efficacy data from the INTEGRIS-PSC Phase 2a trial of Bexotegrast 320 mg)
- HPK +5.2% (announced a 60% increase to its quarterly dividend to $0.04 per share and a $75 mln share repurchase authorization)
- ELAN +5.2% (Merck (MRK) announced that it has signed a definitive agreement to acquire the aqua business of ELAN for $1.3 billion in cash)
- GNLX +3.1% (files for $300 mln mixed securities shelf offering)
- TSVT +2.7% (names William Baird as CEO; names Victoria Eatwell as CFO; BMY and TSVT share update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in triple-class exposed multiple myeloma based on KarMMa-3 study)
- MGY +1.6% (announces 13% dividend increase)
- NOK +1.1% (signs 5G patent cross-license agreement with vivo)
- RVPH +1% (files for $200 mln mixed securities shelf offering)
Analyst comments:
- KVYO +4.4% (upgraded to Buy from Neutral at Goldman)
- APLS +3.5% (upgraded to Buy from Hold at Jefferies)
- CFG +1.9% (upgraded to Buy from Neutral at Citigroup)